In 2012, Biomet paid more than $22 million to settle SEC and Department of Justice violations of the Foreign Corrupt Practices Act (FCPA). From 2000 to August 2008 Biomet bribed publicly employed doctors in Argentina, Brazil, and China with up to 15-20% of the sale. The four subsidiaries involved were Biomet Argentina SA, U.S. subsidiary Biomet International, Biomet China and Scandimed AB.[10]